SC12: Design Strategies and Development of ADCs

THURSDAY, APRIL 11, 5:45 - 8:15 PM (Back Bay Complex)

Instructor:

Robert Lutz, PhD, Principal Consultant, Crescendo Biopharma Consulting

Introduction:

Recent innovations in ADC technologies provide new opportunities for successful drug development. What are the critical design factors? What are the considerations for successful ADC development? This short course will review ADC design concepts and strategies for ADC development.

Agenda:

• Review of the recent innovations for ADC components: binders, bioconjugation, linkers and payloads
• Assessment of ADC design goals
• Review of ADC development goals
• Biomarker strategies – patient selection
• Q&A

Who Should Attend:

This course is appropriate for ADC researchers and development team members interested in ADC design and development.
Research associates, scientists, business development managers, project managers, etc.

About the Instructor:

Robert Lutz, PhD, Principal Consultant, Crescendo Biopharma Consulting

Bob has been an independent consultant in the biotech/pharma industry since 2015 and has worked with multiple clients providing strategic, tactical and operational input for their research and development efforts. Prior to initiating his consulting practice, Bob held various R&D roles over a 23 year span at ImmunoGen, Inc. In his most recent position at ImmunoGen, Bob was Vice President of Translational Research and Development with responsibility for all early stage antibody drug conjugate (ADC) development programs from lead identification through phase 2. He also served as ImmunoGen’s research lead on Genentech’s FDA-approved trastuzumab emtansine (T-DM1) program. Before the ADC research position, Bob was part of ImmunoGen’s Apoptosis Technology Inc subsidiary where he led the research collaboration leading to the discovery of the BH3 domain of the BCl-2 family of death regulatory proteins. Before ImmunoGen, Bob was a research and postdoctoral fellow at the Eleanor Roosevelt Institute in Colorado. He earned his doctoral degree in Biochemistry at Brandeis University.